Louis P. Garrison

Oct 10, 2024 | healthaffairs.org | Adrian Towse |Louis P. Garrison

The Inflation Reduction Act (IRA) of 2022 includes a complex set of provisions that will have the effect of reducing and reorienting federal spending on medicines for the elderly and disabled. The IRA marks a transformative shift in US policy by authorizing the Centers for Medicare and Medicaid Services (CMS) to implement a Medicare Drug Price Negotiation Program (MDPNP) to decrease spending on eligible drugs in Medicare Parts B and D by establishing a Maximum Fair Price (MFP) for them.

May 6, 2024 | statnews.com | Jason Shafrin |Louis P. Garrison |Melanie D. Whittington

The changing landscape of drug pricing policy in the U.S. has implications for the global pace and direction of innovation. Drug policy changes are being influenced by perceptions of the value of novel medicines relative to their budgetary impacts, with some believing that many medicines may not be worth their cost, creating an important role for health technology assessments (HTA).

Apr 3, 2024 | biospace.com | Kirsten Axelsen |Louis P. Garrison

Pictured: Collage of woman and financial elements/Taylor Tieden for BioSpace The federal government could save $25 billion in 2031 from the Inflation Reduction Act (IRA) that aims to reduce prescription drug spending, but an estimated 15 new drugs, or about 1% of total number of expected approvals, may fail to hit the market over the next 30 years as a result of reduced revenue for the biopharma industry.

Jun 5, 2023 | healthaffairs.org | Louis P. Garrison |Adrian Towse

The Inflation Reduction Act (IRA) of 2022 Section 1193 states that when engaging in drug price negotiation, the Secretary of Health and Human Services should consider, among multiple factors, manufacturer-submitted data on the drug’s “research and development costs,” as well as “the extent to which the manufacturer has recouped research and development [R&D] costs.” And in its initial March 15, 2023, guidance for implementation of the Negotiation Program, the Centers for Medicare and Medicaid...

Jun 5, 2023 | tinyurl.com | s’ Note |Louis P. Garrison |Adrian Towse

The Inflation Reduction Act (IRA) of 2022 Section 1193 states that when engaging in drug price negotiation, the Secretary of Health and Human Services should consider, among multiple factors, manufacturer-submitted data on the drug’s “research and development costs,” as well as “the extent to which the manufacturer has recouped research and development [R&D] costs.” And in its initial March 15, 2023, guidance for implementation of the Negotiation Program, the Centers for Medicare and Medicaid...